2018/01/29 by John M. Lambert, Anna Berkenblit · 307 citations
Chemistry · Medicine · #Anaplastic large-cell lymphoma #Antibody #Antibody-drug conjugate #Breast cancer #Brentuximab vedotin #CD30 #Calicheamicin #Cancer #Cancer research #Chemistry #Clinical trial #Cytotoxic T cell #Drug #HER2/EGFR in Cancer Research #Immunology #Immunotoxin #In vitro #Internal medicine #Lymphoma #Lymphoma Diagnosis and Treatment #Medicine #Metastatic breast cancer #Monoclonal and Polyclonal Antibodies Research #Monoclonal antibody #Oncology #Pharmacology #Trastuzumab #Trastuzumab emtansine
paper · pdf · doi:10.1146/annurev-med-061516-121357
published in Annual Review of Medicine 69(1), 191-207 (Annual Reviews)
openalex publication_date 2018/01/29 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/25
The concept of exploiting the specific binding properties of monoclonal antibodies as a mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to the challenge of increasing the therapeutic index of cell-killing agents for treating cancer. All three parts of an antibody-drug conjugate (ADC)-the antibody, the cytotoxic payload, and the linker chemistry that joins them together-as well as the biologic properties of the cell-surface target antigen are important in designing an effective anticancer agent. The approval of brentuximab vedotin in 2011 for treating relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, and the approval of ado-trastuzumab emtansine in 2013 for treating HER2-positive metastatic breast cancer, have sparked vigorous research in the field, with >65 ADCs currently in clinical evaluation. This review highlights the ADCs that are approved for marketing, in pivotal clinical trials, or in at least phase II clinical development for treating both hematologic malignancies and solid tumors.